Free Access
Med Sci (Paris)
Volume 19, Number 11, Novembre 2003
Page(s) 1146 - 1151
Section M/S Revues
Published online 15 November 2003
  1. Schwoebel V, Hubert B, Desenclos JC. Investigations à conduire autour d’un cas de tuberculose ou de primo-infection tuberculeuse récente. BEH 1994; 9: 39–42. [Google Scholar]
  2. Styblo K. Recent advances in epidemiological research in tuberculosis. Adv Tuberc Res 1980; 20: 1–63. [Google Scholar]
  3. Van Soolingen D. Molecular epidemiology of tuberculosis and other mycobacterial infections: main methodologies and achievements. J Intern Med 2001; 249: 1–26. [Google Scholar]
  4. Geng E, Kreiswirth B, Driver C, et al. Changes in the transmission of tuberculosis in New York City from 1990 to 1999. N Engl J Med 2002; 346: 1453–8. [Google Scholar]
  5. INVS (Institut de veille sanitaire). Impact épidémiologique d’une modification de la politique de vaccination par le BCG en France. Revue de la littérature et analyse des données disponibles. Saint-Maurice: INVS, 2001. [Google Scholar]
  6. Behr MA, Warren SA, Salamon H, et al. Transmission of Mycobactrium tuberculosis from patients smearnegative for acid-fast bacilli. Lancet 1999; 353: 444–9. [Google Scholar]
  7. Decludt B, Campese C. Les cas de tuberculose déclarés en France en 2000. BEH 2002; 16-17: 68–70. [Google Scholar]
  8. Infuso A, Antoine D, Barboza P, Euro TB. Surveillance européenne de la tuberculose en 1999 et tendances récentes. BEH 2002; 16-17: 66–7. [Google Scholar]
  9. WHO (World health organization). Antituberculosis drug resistance in the world. Report n°2. Prevalence and trends. Genève: WHO, 2000. [Google Scholar]
  10. CDC (Centers for disease control and prevention). Epidemiologic notes and reports. Nosocomial transmission of multidrugresistant tuberculosis among HIV-infected persons, Florida and New York, 1988-1991. MMWR Morb Mortal Wkly Rep 1991; 40: 585–91. [Google Scholar]
  11. Robert J, Trystram D, Truffot-Pernot C, Jarlier V. Surveillance de la tuberculose à bacilles multirésistants en France en 1998. BEH 2002; 16-17: 73–6. [Google Scholar]
  12. Schluger NW, Rom WN. The host immune response to tuberculosis. Am J Respir Crit Care Med 1998; 157: 679–91. [Google Scholar]
  13. Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. Consensus statement. global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO global surveillance and monitoring project. JAMA 1999; 282: 677–86. [Google Scholar]
  14. Badri M, Wilson D,Wood R. Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet 2002; 359: 2059–64. [Google Scholar]
  15. INVS (Institut de veille sanitaire). Surveillance du SIDA en France. Situation au 31 mars 2002. BEH 2002; 27: 133–8. [Google Scholar]
  16. CDC (Centers for disease control and prevention). Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Recomm Rep 2000; 49: RR–6. [Google Scholar]
  17. Gordin FM, Chaisson RE, Matts JP, et al. An international randomized trial of rifampin and pyrazinamide versus isoniazid for prevention of tuberculosis in HIVinfected persons. JAMA 2000; 283: 1445–50. [Google Scholar]
  18. Bailey WC, Gerald LB, Kimerling ME, et al. Predictive model to identify positive tuberculosis skin test results during contact investigations. JAMA 2002; 287: 996–1002. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.